Is There a Future for AKT Inhibitors in the Treatment of Cancer?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26979397.
- Also identified by DOI 10.1158/1078-0432.CCR-16-0100 and PMC identifier 4891224.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER(+)/HER2(-) breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway. Clin Cancer Res; 22(11); 2599-601. ©2016 AACRSee related article by Ma et al., p. 2650.
Medical subject headings
- Breast Neoplasms
- Receptors, Estrogen